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FayoumAbstract Background and objectives: Patients with beta thalassemia major are at higher risk of
acquiring reticulocytopenia, and cessation of erythropoiesis after exposure to parvovirus B19.
The aim of the study was to detect the seroprevalence of parvovirus B19 infection in children with
transfusion dependent beta-thalassemia major through the detection of its specific IgM and IgG in
their sera by Enzyme-linked Immunosorbent Assay (ELISA) in the Pediatric Department of
Fayoum University Hospital.
Materials and methods: A cross sectional descriptive study was carried out from July to September
2013, in the Pediatric Department of Fayoum University Hospital in Egypt. A total of fifty-five chil-
dren with beta-thalassemia major aged from 2 to 16 years were enrolled in the study. All patients
were subjected to history taking, examination and investigations including; Complete blood count,
serum creatinine, blood urea, hepatitis B surface antigen (HBsAg), anti hepatitis C virus antibody
(anti HCV), reticulocytic count, anti B19 IgM and IgG.
Results: Anti-B19 IgM antibodies (recent infection) were detected in 14.5% (8 patients), while anti
B19 IgG antibodies (prior infection) were detected in 18.2% (10 patients) of transfusion dependent
thalassemic patients. There was a significant statistical correlation between the history of other sib-
lings with beta thalassemia major, the hepatitis C virus and hepatitis B virus infection regarding
absent, prior and recent infection.
Conclusion: Parvovirus B19 infection is detected in high rates among children with beta tha-
lassemia major. Measures to avoid iatrogenic and nosocomial transmission have to be implemented
including screening of donated blood for B19 especially blood given to patients with hematological
disorders. Also data from this study support the need for introduction of an approved B19 vaccine
that primarily protects children with thalassemia major against that infection.
 2016 The Egyptian Pediatric Association. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).BsAg,
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In Egypt, it was estimated that 1.000/1.5 million per year live
births will suffer from thalassemia.1 Patients with beta
thalassemia major, are at higher risk of acquiring aplastic cri-
sis, sudden worsening of anemia, reticulocytopenia, and cessa-
tion of erythropiosis of the bone morrow after exposure to
parvovirus B19.2 Also B19 infection results in a severe drop
of hemoglobin values and anemia which could be life-
threatening.3 Transmission of B19 occurs via respiratory dro-
plets, contaminated blood, organ transplantation and vertical
transmission from mother to fetus.4
The aim of this study was to detect the seroprevalence of
parvovirus B19 infection in multitransfused beta-thalassemia
major patients at Pediatric Department of Fayoum University
Hospital.Materials and methods
A cross sectional descriptive study was carried out from July to
September 2013, in the Pediatric Department of Fayoum
University Hospital in Egypt. A total of 55 children (26 female
and 29 male) aged from 2 to 16 years with mean age 6.2
± 13.25 years were enrolled in the study; all of them have
transfusion dependent beta thalassemia major and are
receiving medical care at Pediatric Department of Fayoum
University Hospital. All patients were under a hypertransfu-
sion regimen and treated with regular transfusion of packed
red blood cells. Exclusion criteria were patients with other
hemoglobinopathies such as sickle cell anemia and anemia
due to other causes.
All the included subjects were treated according to the
Helsinki Declaration of biomedical ethics,5 informed consent
was obtained from the parents, and the Ethics Committee of
the Medical Faculty of Fayoum University approved the study
protocol.
Data collection was carried out using a field pre-tested
interviewing questionnaire covering the following elements:
 History of thalassemia; complications and frequency of
blood transfusion along the course of the disease.
 History of B19 infections manifestations; characteristic
‘‘slapped cheeks” rash, joint manifestations, previous or
recent episodes of transient aplastic crisis ‘‘TAC” (severe
pallor, tachycardia, tachypnea ±a rash).
 History of vaccination especially to hepatitis B virus.
A fully detailed clinical examination for identifying recent
B19 infections and the manifestations of the chronic hemato-
logic conditions was done, documented in the form of check-
lists for B19 fulfilling all useful items of personal data,
history and clinical examination.Collection of all lab data from
patients’ files e.g. CBC, kidney function (urea and creatinine),
liver functions (ALT and AST) and hepatitis B and C virus
status.
Sample collection and preparation
Ten milliliters of blood was drawn from the antecubital fossa
of each subject after obtaining informed consent. The 10 mlof blood was divided into two aliquots, 3 ml was added into
EDTA anticoagulated bottle and was used for basic complete
blood count (CBC), while the remaining 7 ml was added into a
plain specimen container allowed to clot. After clotting, blood
samples in the plain tubes were centrifuged at 3000 rpm for
10 min and the resulting sera were collected into separate cryo
tubes for biochemistry and serological analysis of B19 IgM
and IgG antibodies. The serum samples were used immediately
or stored at 20 C until tested.
Determination of IgG and IgM antibodies against parvovirus
B19 by in vitro diagnostic Enzyme immunoassay
Quantitative immunoenzymatic determination of IgG and
IgM antibodies against B19 based on the ELISA (Enzyme-
linked Immunosorbent Assay) technique, using one of the
commercially available ELISA kits (RIDASCREEN B19
IgG kits) manufactured by R-Biofarm, Germany, with test
sensitivity 91.3% and specificity 100%.
 According to the results of parvovirus B19 IgG and IgM
antibodies by ELISA, patients were categorized into:No infection if both Ig M &Ig G were negative;
prior infection if IgG +ve and IgM ve;
recent infection if IgM +ve and IgG ve or +ve.
Statistical analysis
Data were coded and entered using the statistical package
SPSS version 15. The data were summarized using descriptive
statistics: mean, standard deviation, median, minimum and
maximum values for quantitative variables and number and
percentage for qualitative values. Statistical differences
between groups were tested using Chi Square test for qualita-
tive variables, independent sample test and ANOVA (analysis
of variance) with postHoc Scheffe test for quantitative nor-
mally distributed variables while nonparametric Mann–Whit-
ney test and Kruskal–Wallis test were used for quantitative
variables which aren’t normally distributed. P-values less than
or equal to 0.05 were considered statistically significant.Results
A total of 55 children were enrolled in the study: 22 patients
(40%) aged <5 years, 26 patients (47.2%) aged 5–10 years
and 7 patients (12.8%) aged >10 years. According to the
results of parvovirus B19 IgG and IgM antibodies by ELISA,
it was found that 37 patients (67.3%) had no infection (both
IgM & IgG were negative), 10 patients (18.2%) had prior
infection (IgG +ve & IgM ve) and 8 patients (14.5%) had
recent infection (IgM +ve & IgG ve or +ve). As regards
the clinical manifestations of parvovirus B19; transient aplastic
crises were found in 2 patients (3.6%) also 2 patients (3.6%)
had a history of arthralgia and no one had a rash while
96.4% were asymptomatic. History of vaccination against
hepatitis B was irrelevant. As regard to number of blood trans-
fusions: Of children who received less than 10 blood transfu-
sion (6 patients), 2 of them had no infection, 2 had prior
infection and 2 had recent infection. Of children who received
more than 10 blood transfusions (49 patients), 35 of them had
Table 1 Comparison of some complications among study groups.
Variable Absent infection Prior Recent P value
No. % No. % No. %
History of splenectomy
Yes (6 patients) 2 33.3% 3 50.0% 1 16.7% 0.085
No (49 patients) 35 71.91% 7 14.3% 7 14.3%
Pathological fractures
Yes (15 patients) 10 66.7% 2 13.3% 3 20.0% 0.708
No (40 patients) 27 67.5% 8 20.0% 5 12.5%
Intercurrent infection
Yes (21 patients) 14 66.7% 5 23.8% 2 9.5% 0.554
No (34 patients) 23 67.6% 5 14.7% 6 17.6%
HCV
+ve (5 patients) 0 0% 3 60.0% 2 40.0% 0.003*
ve (50 patients) 37 74% 7 14.0% 6 12.0%
HBV
+ve (2 patients) 0 0% 2 100% 0 0% 0.028*
ve (53 patients) 37 69.8% 8 15.1% 8 15.1%
HCV; hepatitis C virus HBV; hepatitis B virus.
* P value 60.05 is significant.
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value between the 2 groups was insignificant (0.162).
History of other siblings with beta thalassemia major was
positive with 15 patients; 2 of them had no infection, 8 had
prior infection and 5 had recent infection. It was negative with
40 patients; 35 of them had no infection, 2 had prior infection
and 3 had recent infection. P value between the 2 groups was
significant (0.001).
Age below 5 years (21 patients); 17 of them had no infec-
tion, 1 had prior infection and 3 had recent infection. Age from
5 to 10 years (26 patients); 17 of them had no infection, 6 had
prior infection and 3 had recent infection. Age more than
10 years (8 patients); 3 of them had no infection, 3 had prior
infection and 2 had recent infection. P value between the 3
groups was insignificant; (0.166).
Table 1 shows that 10.9% (6 patients) had a history of
splenectomy, 38.2% (21 patients) had a history of intercurrent
infection, 27.3% (15 patients) had a history of pathological
fractures, 9.1% (5 patients) had HCV infection, and 3.6% (2
patients) had HBV infection. There was a significant statistical
correlation between the HCV and HBV infection regarding
absent, prior and recent infections.
Table 2 shows that there was a significant statistical corre-
lation between Hb% and retics with B19 seroprevalence. There
were statistically significant difference between thalassemic
patients of recent and absent infections and thalassemic patient
of recent and prior infections.
Table 3 shows that there was no significant statistical corre-
lation between BUN, creatinine and ALT with B19
seroprevalence.
Discussion
Patients with beta thalassemia major are at higher risk of
acquiring aplastic crisis, sudden worsening of anemia, reticulo-
cytopenia, and cessation of erythropoiesis of the bone morrow(transient aplastic crisis) after exposure to parvovirus B19
infection.4 The aim of this study was to detect the prevalence
of parvovirus B19 in children with transfusion dependent
beta-thalassemia major through the detection of its specific
IgM and IgG in their sera by ELISA.
In the present study, the prevalence of B19 specific IgG
(prior infection) was 18.2% while the prevalence of B19 speci-
fic IgM (recent infection) was 14.5%, comparable to other
studies in Tunis (75 cases) it was 0% for IgM and 39.1% for
IgG,6 in Iraq (46 cases) it was 13% for IgM and 30.4% for
IgG7 and in India (90 cases) it was 40.1% for IgM and 81%
for IgG.8 All the variations in B19 seropositivity between dif-
ferent regions of the world, clarify that climate, variable
socioeconomic status, overcrowding and geographical distri-
bution may have effective influence on B19 seroprevalence. It
may also be attributed to difference in immunological and/or
hematological status of participants.
In the present study, prior B19 infection (as diagnosed by
presence of IgG only) had a higher rate (18.2%) than recent
infection (14.5%). In accordance with another Egyptian study,
who reported 40% prevalence of prior B19 infection in various
types of chronic hemolytic anemia they reported a lower rate
of recent infection (24%).9 This difference in rate of recent
B19 infection may be attributed to different socioeconomic
standards, frequency of blood transfusions and possibility of
nosocomial exposure.
This work showed no significant association between B19
seroprevalence and the number of blood transfusions. This is
in accordance with Iheanacho et al. who found that there is
no statistically significant difference between the control group
and the sickle cell anemia patients as regards the seropreva-
lence of B19 infection.10 This may suggest that blood transfu-
sion may not be the major means of transmission of
parvovirus. Contrary to our findings, Lee et al., reported
increased seropositive rates of parvovirus infections associated
with blood transfusion.11
Table 2 Comparison of hematological parameters among study groups.
Variable Absent infection
Mean ± SD
Prior
Mean ± SD
Recent
Mean ± SD
P value
Red blood cells
1012/l
2.69 ± 0.39 3.00 ± 0.53 2.20 ± 0.66 P 0.002
P1 0.173
P2 0.030
P3 0.002
Hemoglobin
gm/dl
6.78 ± 0.69 7.24 ± 0.75 5.89 ± 1.34 P 0 .004
P2 0.300
P2 0.026
P3 0.004
Total leukocytes count
109/l
12.50 (5.90:68.40) 11.5 (5.90:47.05) 9.36 (4.76:11.20) P 0.056
P1 0.086
P2 0.074
P3 0.068
Platelets
109/l
312 (183:661) 355 (221:494) 277 (127:340) P 0.261
P1 0.841
P2 0.378
P3 0.287
Retics
%
3.45 (2.82:4.52) 3.47 (2.87:4.12) .62 (0.45:3.67) P 0.016
P1 0.876
P2 0.004
P3 0.033
P value 60.05 is significant (test was done using ANOVA and PostHoc test). P1 = statistical difference between absent and prior infection.
P2 = statistical difference between absent and recent infection. P3 = statistical difference between prior and recent infection.
Table 3 Comparison of laboratory parameters among study groups.
Variable Absent infection
Mean ± SD
Prior
Mean ± SD
Recent
Mean ± SD
P value
ALT
IU/l
26.00 (11:160) 32.00 (18:341) 43.50 (14:140) P 0.180
P1 0.145
P2 0.163
p3 0 .824
AST
IU/l
32.00 (20:92) 34.50 (22:240.90) 44 (24:102) P 0.262
P1 0.292
P2 0.167
P3 0.450
BUN
mg/dl
25.46 ± 6.36 24.00 ± 4.11 27.03 ± 4.34 P 0.572
P1 0.782
P2 0.808
P3 0.578
Creatinine
mg/dl
0.42 ± 0.09 0.40 ± 0.08 0.40 ± 0.08 P 0.722
P1 0.802
P2 0.847
P3 1.00
BUN: blood urea nitrogen ALT: alanine transaminase AST: aspartat transaminase. P value 60.05 is significant (test was done using Mann
Whitney test and Kruskal–Wallis test). P1 = statistical difference between absent and prior infection. P2 = statistical difference between absent
and recent infection. P3 = statistical difference between prior and recent infection.
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prevalence of B19 and history of other siblings in the family
with beta-thalassemia major. This is consistent with Alao
et al. who reported that B19 is known to be highly infectious.
The secondary attack rates between 50% and 60% have been
reported.12
This study evaluated the hematological profile of tha-
lassemic patients with and without IgG seropositivity. There
were no significant differences in hemoglobin concentration,total leukocytic count, platelet count and reticulocytic count
between IgG seropositive (prior infection) and IgG seronega-
tive (absent infection) thalassemic patients. This may be
explained by that the presence of this class of antibody is gen-
erally indicative of either the later stages of a current infection,
or of a past infection. Thus these findings are in keeping with
the well documented observation that; If a patient survives the
transient marrow aplasia, recovery is usually complete and no
clinical or hematological traces of previous infection are
130 M.E. Al Ghwass et al.found.13 In contrast with Girei et al. who found statistically
significant difference in the mean absolute platelet count
between IgG seropositive and IgG seronegative subjects.14
Our study revealed that the mean hemoglobin concentra-
tion and the mean reticulocyte index are lower among IgM
seropositive thalassemic subjects (recent infection) as
compared to IgM seronegative (absent infection) and IgG
seropositive (prior infection) thalassemic subjects and the dif-
ferences were statistically significant. Also, we found that the
mean absolute platelet count and the mean total leukocytic
count were lower among IgM seropositive subjects as com-
pared to IgM seronegative and IgG seropositive subjects but
the differences were not statistically significant. The latter
results are similar to Zaki et al. and Ensaf et al. who reported
anemia and reticulocytopenia as a constant feature in patients
with hematologic disorders recently infected with B19.15,9
Our study revealed that the mean ALT is higher among
IgM seropositive thalassemic subjects (recent infection) as
compared to IgM seronegative (absent infection) and IgG
seropositive (prior infection) thalassemic subjects but the dif-
ferences were not statistically significant. In agreement with
Bamidele et al. who reported that parvovirus B19 infection
caused elevation in liver enzymes in infected sickle cell anemia
patients and the differences were statistically significant.16
The present study showed no significant association
between B19 and HCV and HBV infection. Co-existence of
B19 infection along with HBV and HCV was seen in two
(3.6%) and five (9.1%) thalassemic patients respectively. In
agreement with a study done by Kishore et al. who found that
co-existence of B19 infection along with HBV and HCV was
seen in four (4.4%) and seven (7.7%) thalassemia patients
respectively.8 This is explained by that the thalassemic patients
are on a hyper-transfusion regimen, hence, are at higher risk of
acquiring transfusion transmitted viruses.
Our study has some limitations, we could not figure out
whether transient aplastic crises (TAC) had been significantly
presented among our thalassemic patients of prior infection.
Not even a single documented diagnosed TAC attack was pre-
sent in their medical reports. Also, we could not demonstrate
its incidence or impact on their health status. This may be
explained by the underestimation of B19 BM aplasia (i.e. we
always search first for other viral causes as EBV, hepatitis
viruses, secondary drug causes or others). Again lack of
human parvovirus B19 diagnostic tools in our laboratories is
another reason. Moreover the hypertransfusion regimen in
managing thalassemic patients may bridge the gap between
BM suppression and its recovery concealing TACs. The sero-
prevalence of B19 in normal Egyptian population is not
known. Finally the direct detection of DNA by PCR in sera
needs to be coupled to serology for a more reliable diagnosis
of B19 infections in those children.
Conclusions
Parvovirus B19 infection is detected in high rates among chil-
dren with beta thalassemia major (prior infection; 18.2% and
recent infection; 14.5%). It should be suspected when a tha-
lassemic child develops a sudden drop in hemoglobin (TAC)
and when other siblings with beta thalassemia are seropositive
for B19. In Egypt, further researches are needed to detect B19
prevalence among our general pediatric population. Measuresto avoid iatrogenic and nosocomial transmission have to be
implemented including screening of donated blood for B19
especially blood given to patients with hematological disorders.
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